← Arcus Biosciences, Inc.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income From Continuing Operations — ($53.1m) ($49.6m) ($84.7m) ($122.9m) $52.8m ($267.0m) ($307.0m) ($283.0m) ($353.0m) ($460.0m)
Net loss ($18.0m) ($53.1m) ($49.6m) ($84.7m) ($122.9m) $52.8m ($267.0m) ($307.0m) ($283.0m) ($353.0m) —
Depreciation and amortization $1.3m $2.6m $3.7m $3.6m $3.1m $3.8m $6.0m $8.0m $10.0m $10.0m $10.0m
Amortization of discounts on marketable securities $0 $0 ($1.8m) ($2.6m) ($46k) $4.8m $0 ($19.0m) ($25.0m) ($13.0m) —
Amortization Of Securities — — — — — — $0 ($19.0m) ($25.0m) ($13.0m) ($11.0m)
Depreciation Amortization Depletion — — — — — — $6.0m $8.0m $10.0m $10.0m $10.0m
Share-based Payment Arrangement, Noncash Expense — $495k $3.9m $9.0m $21.8m $54.5m $65.0m $73.0m $76.0m $60.0m $63.0m
Payment, Tax Withholding, Share-based Payment Arrangement — — — — — — — — $7.0m $0 —
Share-based Payment Arrangement, Expense — — — — — — $65.0m $73.0m $76.0m $60.0m $63.0m
Stock-based compensation expense $90k $495k $3.9m $9.0m $21.8m $54.5m $65.0m $73.0m $76.0m $60.0m $63.0m
Operating Lease, Impairment Loss — — — — — — — — $20.0m $0 —
Impairment on right-of use assets — — — — — — $0 $0 $20.0m $0 —
Asset Impairment Charge — — — — — — $0 $0 $20.0m $0 $0
Income (Loss) from Equity Method Investments — ($416k) ($886k) ($1.2m) ($613k) — — — — — —
Nonoperating Income (Expense) — $359k $5.3m $4.0m $1.4m $397k $14.0m $39.0m $48.0m $33.0m —
Changes in operating assets and liabilities:
Change In Working Capital — — — — — — $623.0m ($71.0m) $22.0m ($194.0m) ($87.0m)
Change In Receivables — — — — — — $704.0m $15.0m $28.0m $9.0m $9.0m
Increase (Decrease) in Accounts Payable — ($267k) ($69k) $1.7m $9.3m ($4.8m) $8.0m ($1.0m) $3.0m $24.0m $5.0m
Accounts payable ($24, $—, and $— to a related party) $3.6m ($267k) ($69k) $1.7m $9.3m ($4.8m) $8.0m ($1.0m) $3.0m $24.0m $5.0m
Deferred revenue (($240), ($56) and ($77) to a related party) — — ($353k) ($2.0m) $178.4m ($367.9m) ($112.0m) ($68.0m) ($56.0m) ($240.0m) —
Other assets ($—, $6 and ($4) from a related party) ($200k) ($6k) ($80k) ($588k) ($5.4m) $3.3m $2.0m ($14.0m) $22.0m $5.0m —
Other liabilities — — — — $10.2m ($498k) $21.0m ($3.0m) $25.0m $8.0m —
Change In Other Current Assets — — — — — — $2.0m ($14.0m) $22.0m $5.0m $3.0m
Change In Other Current Liabilities — — — — — — $21.0m ($3.0m) $25.0m $8.0m $2.0m
Net Cash Provided by (Used in) Operating Activities ($12.9m)
($25.1m) -93.60%
($43.0m) -71.58%
($73.5m) -70.86%
$111.2m +251.33%
($256.2m) -330.43%
$438.0m +270.98%
($306.0m) -169.86%
($170.0m) +44.44%
($482.0m) -183.53%
($474.0m) +1.66%
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment ($4.1m) $5.5m $3.7m $1.9m $3.1m $26.1m $6.0m $24.0m $6.0m $2.0m ($3.0m)
Debt Securities, Available-for-sale, Realized Gain (Loss) — — — — — $0 — — — — —
Purchases of marketable securities — — — — ($740.0m) ($719.0m) ($1.2b) ($788.0m) ($1.0b) ($1.1b) —
Proceeds from maturities of marketable securities — — — — $308.0m $690.0m $694.0m $982.0m $929.0m $1.1b —
Proceeds from sales of marketable securities — — — — $1.0m $51.0m $143.0m $24.0m $36.0m $71.0m —
Payments to Acquire Investments — $96.8m $261.6m $247.8m $739.7m $718.9m — — — — ($894.0m)
Payments for (Proceeds from) Other Investing Activities — — — — — — — — $0 — —
Net Cash Provided by (Used in) Investing Activities ($38.9m) ($49.1m) ($113.4m) $59.2m ($434.4m) ($3.9m) ($413.0m) $194.0m ($84.0m) $66.0m $63.0m
Cash flows from financing activities:
Proceeds from debt issuances, net — — — — — — $0 $0 $47.0m $49.0m —
Issuance Of Debt — — — — — — $0 $0 $47.0m $49.0m $0
Long Term Debt Issuance — — — — — — $0 $0 $47.0m $49.0m $0
Net Issuance Payments Of Debt — — — — — — $0 $0 $47.0m $49.0m $0
Issuance Of Capital Stock — — — — — — $0 $25.0m $228.0m $429.0m $287.0m
Proceeds from Issuance of Common Stock — — $4.1m $1.2m $433.8m $220.2m $0 $25.0m $228.0m $429.0m $287.0m
Proceeds from issuance of common stock pursuant to equity award plans — — $4.1m $1.2m $5.0m $12.1m $23.0m $8.0m $9.0m $10.0m $287.0m
Common Stock Issuance — — — — — — $0 $25.0m $228.0m $429.0m $287.0m
Payments for Repurchase of Common Stock — — — $94k — — — — — — —
Net Other Financing Charges — — — — — $5.0m $10.0m — ($7.0m) — ($7.0m)
Net Cash Provided by (Used in) Financing Activities $70.1m
$107.4m +53.20%
$129.1m +20.19%
$1.1m -99.13%
$438.7m +38962.78%
$237.3m -45.90%
$33.0m -86.10%
$33.0m 0.00%
$277.0m +739.39%
$488.0m +76.17%
$313.0m -35.86%
Net increase (decrease) in cash, cash equivalents and restricted cash — — ($27.4m) ($13.1m) $115.5m ($22.7m) $58.0m ($79.0m) $23.0m $72.0m —
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect — — — ($13.1m) $115.5m ($22.7m) $58.0m ($79.0m) $23.0m $72.0m $153.0m
Beginning Cash Position — — — — — — $151.0m $209.0m $130.0m $153.0m $251.0m
Cash, cash equivalents and restricted cash at beginning of period — — $71.3m $58.1m $173.6m $150.9m $209.0m $130.0m $153.0m $225.0m —
Additional Supplementary Disclosures
Additional Supplementary Disclosures
Income Tax Expense (Benefit) — — — — — $1.8m $1.0m $6.0m $1.0m $0 —
Interest Expense Nonoperating — — — — — — — — $4.0m $8.0m —
Additional Financial Items
General and Administrative Expense — $7.6m $13.6m $25.2m $42.4m $72.3m $104.0m $117.0m $120.0m $110.0m —
Operating Expenses — $54.9m $63.2m $103.7m $201.8m $328.6m $392.0m $457.0m $588.0m $633.0m —
Financing Receivable, Credit Loss, Expense (Reversal) — — — — — $0 $0 $0 $0 $0 —
Noncash lease expense — — — — $1.0m $3.2m $8.0m $8.0m $7.0m $7.0m —
Other items, net — — — — — $0 $3.0m $2.0m $0 $1.0m —
Receivable from collaboration partners ($6, $14 and $19 from a related party) — — $0 ($132k) ($917k) ($17.0m) $704.0m $15.0m $28.0m $9.0m —
Payments of employee taxes related to net settlement of equity awards — — — — — — $0 $0 ($7.0m) $0 —
Cash Flow From Continuing Financing Activities — — — — — — $33.0m $33.0m $277.0m $488.0m $313.0m
Cash Flow From Continuing Investing Activities — — — — — — ($413.0m) $194.0m ($84.0m) $66.0m $63.0m
Change In Account Payable — — — — — — $8.0m ($1.0m) $3.0m $24.0m $5.0m
Change In Other Working Capital — — — — — — ($112.0m) ($68.0m) ($56.0m) ($240.0m) ($106.0m)
Change In Payable — — — — — — $8.0m ($1.0m) $3.0m $24.0m $5.0m
Changes In Cash — — — — — — $58.0m ($79.0m) $23.0m $72.0m ($98.0m)
End Cash Position — — — — — — $209.0m $130.0m $153.0m $225.0m $153.0m
Financing Cash Flow — — — — — — $33.0m
$33.0m 0.00%
$277.0m +739.39%
$488.0m +76.17%
$313.0m -35.86%
Free Cash Flow — — — — — — $432.0m ($330.0m) ($176.0m) ($484.0m) ($475.0m)
Investing Cash Flow — — — — — — ($413.0m) $194.0m ($84.0m) $66.0m $63.0m
Net Intangibles Purchase And Sale — — — — — $0 ($3.0m) $0 — — —
Net PPE Purchase And Sale — — — — — — ($6.0m) ($24.0m) ($6.0m) ($2.0m) ($1.0m)
Other Non Cash Items — — — — — — $11.0m $10.0m $10.0m $8.0m —
Proceeds From Stock Option Exercised — — — — — — $23.0m $8.0m $9.0m $10.0m $26.0m
Purchase Of Intangibles — — — — — $0 ($6.0m) $0 — — —
Purchase Of PPE — — — — — — ($6.0m) ($24.0m) ($6.0m) ($2.0m) ($3.0m)
Sale Of Intangibles — — — — — $0 $3.0m $0 — — —
Stock Based Compensation — — — — — — $65.0m $73.0m $76.0m $60.0m $63.0m
Net Investment Purchase And Sale — — — — — — ($404.0m) $218.0m ($78.0m) $68.0m $64.0m
Purchase Of Investment — — — — — — ($1.2b) ($788.0m) ($1.0b) ($1.1b) ($894.0m)
Sale Of Investment — — — — — — $837.0m $1.0b $965.0m $1.1b $958.0m
Supplemental disclosure of cash flow information:
Change In Cash Supplemental As Reported — — — — — — $58.0m ($79.0m) $23.0m $72.0m —
Interest Paid, Excluding Capitalized Interest, Operating Activities — — — — — — $0 $0 $1.0m $7.0m —
Income Taxes Paid, Net — — — — — $0 $3.0m $5.0m $0 $0 —

Amounts are shown in USD as reported in each fiscal year filing.

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.